IceCure Medical Receives Nasdaq Bid Price Notification

Icecure Medical ( (ICCM) ) has shared an update.

On November 14, 2025, IceCure Medical Ltd. announced it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days, until May 11, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. The notice does not immediately affect the company’s Nasdaq listing, and IceCure is considering options to address the deficiency if necessary, to maintain its listing status.

The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Underperform.

Icecure Medical’s overall stock score is primarily impacted by its significant financial challenges, including declining revenues and substantial losses. Technical indicators also show weak momentum, further contributing to a low score. While there is potential regulatory progress with ProSense, financial difficulties and poor valuation metrics weigh heavily on the stock’s outlook.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical Ltd. is a company that develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor treatment. The company’s primary focus areas include breast, kidney, bone, and lung cancer. IceCure’s ProSense® system offers a minimally invasive alternative to traditional surgical tumor removal and is marketed globally, including in the U.S., Europe, and Asia.

Average Trading Volume: 1,632,183

Technical Sentiment Signal: Sell

Current Market Cap: $48.62M

Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.